lifestyle.claritypointe.com

Author: HUTCHMED (China) Limited

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

April 29, 2026
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

April 8, 2026
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

March 22, 2026
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

March 9, 2026
Intended Retirement of Independent Non-executive Director and changes of composition of board committees

March 6, 2026
HUTCHMED Reports 2025 Full Year Results and Business Updates

March 5, 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

March 4, 2026
HUTCHMED to Announce 2025 Final Results

February 11, 2026